Anavex Life Sciences Corp (AVXL)

[F1ash]

“During the Phase 2a 5 week PART A only 2 patients discontinued, resulting in a study retention rate of 94%. During the PART B (voluntary extended participation) to date (26 week) only 3 patients discontinued, resulting in a retention rate of 90% for PART B. Overall retention rate at 31 week is 84%.”

“These results closely reflect the practical course of the study where 25% of the patients remained on their initially allocated dose level of 50 mg while 75% of the total number of patients remained in the 30 mg dose level after five weeks of treatment.

Does this poster actually explain what they did?

Is the “low” concentration group made up of 75% from the 50mg group and 25% from the 30 mg group?

http://www.anavex.com/my_uploads/New-Alzheimers-Drug-ANAVEX-2-73-Phase-2A-Study.pdf

The numbesr seem to work.